{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [
    [
      "COVID-19",
      "LAIV",
      "SARS-CoV-2",
      "coinfection",
      "ferret",
      "live attenuated influenza vaccine"
    ]
  ],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "34893851",
  "DateCompleted": {
    "Year": "2022",
    "Month": "02",
    "Day": "09"
  },
  "DateRevised": {
    "Year": "2022",
    "Month": "02",
    "Day": "09"
  },
  "Article": {
    "ArticleDate": [],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "jiab594",
      "10.1093/infdis/jiab594"
    ],
    "Journal": {
      "ISSN": "1537-6613",
      "JournalIssue": {
        "Volume": "225",
        "Issue": "3",
        "PubDate": {
          "Year": "2022",
          "Month": "Feb",
          "Day": "01"
        }
      },
      "Title": "The Journal of infectious diseases",
      "ISOAbbreviation": "J Infect Dis"
    },
    "ArticleTitle": "Sequential Delivery of Live Attenuated Influenza Vaccine and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in the Ferret Model Can Reduce SARS-CoV-2 Shedding and Does Not Result in Enhanced Lung Pathology.",
    "Pagination": {
      "StartPage": "404",
      "EndPage": "412",
      "MedlinePgn": "404-412"
    },
    "Abstract": {
      "AbstractText": [
        "Cocirculation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and influenza viruses could pose unpredictable risks to health systems globally, with recent studies suggesting more severe disease outcomes in coinfected patients. The initial lack of a readily available coronavirus disease 2019 (COVID-19) vaccine has reinforced the importance of influenza vaccine programs during the COVID-19 pandemic. Live attenuated influenza vaccine (LAIV) is an important tool in protecting against influenza, particularly in children. However, it is unknown whether LAIV administration influences the outcomes of acute SARS-CoV-2 infection or disease. To investigate this, quadrivalent LAIV was administered to ferrets 3 days before or after SARS-CoV-2 infection. LAIV administration did not exacerbate the SARS-CoV-2 disease course or lung pathology with either regimen. In addition, LAIV administered before SARS-CoV-2 infection significantly reduced SARS-CoV-2 replication and shedding in the upper respiratory tract. This study demonstrated that LAIV administration in close proximity to SARS-CoV-2 infection does not exacerbate mild disease and can reduce SARS-CoV-2 shedding."
      ],
      "CopyrightInformation": "\u00a9 The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com."
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "UK Health Security Agency, Porton Down, Salisbury, Wiltshire, United Kingdom."
          }
        ],
        "LastName": "Ryan",
        "ForeName": "Kathryn A",
        "Initials": "KA"
      },
      {
        "Identifier": [
          "0000-0001-9002-5014"
        ],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Flu-BPD, BioPharmaceutical Development, R&D, AstraZeneca, Liverpool, United Kingdom."
          }
        ],
        "LastName": "Schewe",
        "ForeName": "Katarzyna E",
        "Initials": "KE"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Flu-BPD, BioPharmaceutical Development, R&D, AstraZeneca, Liverpool, United Kingdom."
          }
        ],
        "LastName": "Crowe",
        "ForeName": "Jonathan",
        "Initials": "J"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "UK Health Security Agency, Porton Down, Salisbury, Wiltshire, United Kingdom."
          }
        ],
        "LastName": "Fotheringham",
        "ForeName": "Susan A",
        "Initials": "SA"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "UK Health Security Agency, Porton Down, Salisbury, Wiltshire, United Kingdom."
          }
        ],
        "LastName": "Hall",
        "ForeName": "Yper",
        "Initials": "Y"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "UK Health Security Agency, Porton Down, Salisbury, Wiltshire, United Kingdom."
          }
        ],
        "LastName": "Humphreys",
        "ForeName": "Richard",
        "Initials": "R"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "UK Health Security Agency, Porton Down, Salisbury, Wiltshire, United Kingdom."
          }
        ],
        "LastName": "Marriott",
        "ForeName": "Anthony C",
        "Initials": "AC"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "UK Health Security Agency, Porton Down, Salisbury, Wiltshire, United Kingdom."
          }
        ],
        "LastName": "Paterson",
        "ForeName": "Jemma",
        "Initials": "J"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "UK Health Security Agency, Porton Down, Salisbury, Wiltshire, United Kingdom."
          }
        ],
        "LastName": "Rayner",
        "ForeName": "Emma",
        "Initials": "E"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "UK Health Security Agency, Porton Down, Salisbury, Wiltshire, United Kingdom."
          }
        ],
        "LastName": "Salguero",
        "ForeName": "Francisco J",
        "Initials": "FJ"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "UK Health Security Agency, Porton Down, Salisbury, Wiltshire, United Kingdom."
          }
        ],
        "LastName": "Watson",
        "ForeName": "Robert J",
        "Initials": "RJ"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "UK Health Security Agency, Porton Down, Salisbury, Wiltshire, United Kingdom."
          }
        ],
        "LastName": "Whittaker",
        "ForeName": "Catherine J",
        "Initials": "CJ"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "UK Health Security Agency, Porton Down, Salisbury, Wiltshire, United Kingdom."
          },
          {
            "Identifier": [],
            "Affiliation": "Nuffield Department of Medicine, Oxford University, Oxford, United Kingdom."
          }
        ],
        "LastName": "Carroll",
        "ForeName": "Miles W",
        "Initials": "MW"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Flu-BPD, BioPharmaceutical Development, R&D, AstraZeneca, Liverpool, United Kingdom."
          }
        ],
        "LastName": "Dibben",
        "ForeName": "Oliver",
        "Initials": "O"
      }
    ],
    "GrantList": [
      {
        "Agency": "AstraZeneca",
        "Country": ""
      }
    ],
    "PublicationTypeList": [
      "Journal Article",
      "Research Support, Non-U.S. Gov't"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "United States",
    "MedlineTA": "J Infect Dis",
    "NlmUniqueID": "0413675",
    "ISSNLinking": "0022-1899"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Influenza Vaccines"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Vaccines, Attenuated"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [],
      "DescriptorName": "Animals"
    },
    {
      "QualifierName": [
        "therapy"
      ],
      "DescriptorName": "COVID-19"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Disease Models, Animal"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Ferrets"
    },
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Influenza Vaccines"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Lung"
    },
    {
      "QualifierName": [
        "virology"
      ],
      "DescriptorName": "Respiratory System"
    },
    {
      "QualifierName": [
        "physiology"
      ],
      "DescriptorName": "SARS-CoV-2"
    },
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Vaccines, Attenuated"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Virus Replication"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Virus Shedding"
    }
  ]
}